Orchard Plans EU Submission For GSK-Originated MLD Gene Therapy
Orchard is aiming to get its second autologous gene therapy on the market next year, with a European filing for MLD and a BLA to follow.
You may also be interested in...
Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.
Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.